- Home
- PTGX vs NAKA Comparison
PTGX vs NAKA Comparison
Compare PTGX & NAKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- NAKA
- Stock Information
- Founded
- PTGX 2006
- NAKA 2019
- Country
- PTGX United States
- NAKA United States
- Employees
- PTGX N/A
- NAKA N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- NAKA
- Sector
- PTGX Health Care
- NAKA
- Exchange
- PTGX Nasdaq
- NAKA Nasdaq
- Market Cap
- PTGX 5.0B
- NAKA 347.4M
- IPO Year
- PTGX 2016
- NAKA 2024
- Fundamental
- Price
- PTGX $84.49
- NAKA $0.57
- Analyst Decision
- PTGX Strong Buy
- NAKA Strong Buy
- Analyst Count
- PTGX 9
- NAKA 2
- Target Price
- PTGX $86.44
- NAKA $5.00
- AVG Volume (30 Days)
- PTGX 887.0K
- NAKA 28.8M
- Earning Date
- PTGX 11-06-2025
- NAKA 11-05-2025
- Dividend Yield
- PTGX N/A
- NAKA N/A
- EPS Growth
- PTGX N/A
- NAKA N/A
- EPS
- PTGX 0.72
- NAKA N/A
- Revenue
- PTGX $209,217,000.00
- NAKA $2,239,936.00
- Revenue This Year
- PTGX N/A
- NAKA N/A
- Revenue Next Year
- PTGX $140.23
- NAKA $2,755.19
- P/E Ratio
- PTGX $117.62
- NAKA N/A
- Revenue Growth
- PTGX N/A
- NAKA N/A
- 52 Week Low
- PTGX $33.31
- NAKA $0.53
- 52 Week High
- PTGX $93.25
- NAKA $34.77
- Technical
- Relative Strength Index (RSI)
- PTGX 64.48
- NAKA 30.32
- Support Level
- PTGX $82.06
- NAKA $0.53
- Resistance Level
- PTGX $86.90
- NAKA $0.98
- Average True Range (ATR)
- PTGX 3.11
- NAKA 0.07
- MACD
- PTGX 0.14
- NAKA 0.07
- Stochastic Oscillator
- PTGX 77.23
- NAKA 8.90
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About NAKA Kindly MD Inc. Common Stock
Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.